X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders Growth (3y) (2020 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 12.12% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -28.09% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -36.57% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 37.89% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 42.23% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | 33.81% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.81% |
| Mar 31, 2026 | 5.53% |
| Dec 31, 2025 | 6.33% |
| Sep 30, 2025 | -10.85% |
| Jun 30, 2025 | -6.68% |
| Mar 31, 2025 | 26.23% |
| Dec 31, 2024 | -3.51% |
| Sep 30, 2024 | -22.02% |
| Jun 30, 2024 | 87.81% |
| Mar 31, 2024 | -24.39% |
| Dec 31, 2023 | -1.31% |
| Sep 30, 2023 | 49.07% |
| Jun 30, 2023 | -54.37% |
| Mar 31, 2023 | -29.20% |
| Dec 31, 2022 | -39.00% |
| Sep 30, 2022 | -7.28% |
| Jun 30, 2022 | -16.59% |
| Mar 31, 2022 | -28.32% |
| Dec 31, 2021 | -43.95% |
| Sep 30, 2021 | -29.18% |